ArticleBrain and behavior2022
National survey on the current practice and attitudes toward the management of chronic subdural hematoma.
Article in Brain and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Updated systematic review of current randomised controlled trials in chronic subdural haematoma.Acta neurochirurgica · 2025Pooled it
- Success of conservative therapy for chronic subdural hematoma patients: a systematic review.Frontiers in neurology · 2023Pooled it
- Management of chronic subdural hematoma: a consensus statement from the 2024 Copenhagen joint iCORIC/DACSUHS symposium.Acta neurochirurgica · 2026Review
- National survey of current practices and attitudes regarding discharge disposition for older adults with mild traumatic brain injury and traumatic intracranial hemorrhage.Acta neurologica Belgica · 2025Article
- Chronic subdural hematoma management in Thailand: a nationwide survey of clinical practice and trends.Frontiers in neurology · 2025Article
- Chronic subdural hematoma with mild to moderate symptoms: The effect of initial treatment approach on clinical outcome.Brain & spine · 2025Article
- Additional treatment after primary conservative treatment in patients with chronic subdural hematoma-A retrospective study.Brain and behavior · 2024Article
- Factors associated with success of conservative therapy in chronic subdural hematoma: a single-center retrospective analysis.Journal of neurology · 2024Article
- Commentary: Will dexamethasone ever have a role in the management of chronic subdural hematomas?Brain and behavior · 2024Article
- National survey on the current practice and attitudes toward the management of chronic subdural hematoma.Brain and behavior · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic subdural hematoma (CSDH) is a frequent pathological entity in daily clinical practice. However, evidence-based CSDH-guidelines are lacking and level I evidence from randomized clinical trials (RCTs) is limited. In order to establish and subsequently implement a guideline, insight into current clinical practice and attitudes toward CSDH-treatment is required. The aim is to explore current practice and attitudes toward CSDH-management in the Netherlands.
methodsA national online survey was distributed among Dutch neurologists and neurosurgeons, examining variation in current CSDH-management through questions on treatment options, (peri)operative management, willingness to adopt new treatments and by presenting four CSDH-cases.
resultsOne hundred nineteen full responses were received (8% of neurologists, N = 66 and 35% of neurosurgeons, N = 53). A majority of the respondents had a positive experience with burr-hole craniostomy (93%) and with a conservative policy (56%). Around a third had a positive experience with the use of dexamethasone as primary (30%) and additional (33.6%) treatment. These numbers were also reflected in the treatment preferences in the presented cases. (Peri)operative management corresponded among responding neurosurgeons. Most respondents would be willing to implement dexamethasone (98%) if equally effective as surgery and tranexamic acid (93%) if effective in CSDH-management.
conclusionVariation was found regarding preferential CSDH-treatment. However, this is considered not to be insurmountable when implementing evidence-based treatments. This baseline inventory on current clinical practice and current attitudes toward CSDH-treatment is a stepping-stone in the eventual development and implementation of a national guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.